A virus NT was performed in a biosafety level 3 laboratory to determine the titers. A SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) was designed to detect neutralizing antibodies in the serum, based on the binding affinity of SARS-CoV-2 viral protein 1viral protein 2 to antibodies. ELISA results viral protein 12, generated comparable neutralizing antibody titers. The results analyzed by spline regressiontwo-variable generalized additive model precisely reflected the real NT value. Our method can serve as a surrogate to quantify neutralizing antibody titer.

This technology serves as a surrogate to quantifying neutralizing antibody titer which should be performed at P3 laboratory for several days. The new method can be performed at a general laboratorycan obtain the results within 2-3 hours, which has great potential application for clinical use to assess vaccine efficacy.

The technology can measure the amount of neutralizing antibody which correlates to protection efficacy of an individual whether he/she would be infected again by COVID-19. This diagnostic kit will help vaccine efficacy validationhas a great potential to provide laboratory data for so-called “immunity passport”.

天使投資人、策略合作夥伴